Corcept Therapeutics (CORT) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to treat a type of ovarian cancer met its primary goal, sending shares up more than 90% in recent premarket trading activity.
The company said the study showed a 30% reduction in the risk of disease progression for patients treated with relacorilant and nab-paclitaxel compared to those receiving nab-paclitaxel alone.
The drug developer said the median progression-free survival assessed by blinded independent central review was 6.5 months for the combination therapy group, compared to 5.5 months for those on nab-paclitaxel alone.
In an interim evaluation of overall survival, the company said the combination therapy group showed a significant improvement, with a median overall survival of 16 months versus 11.5 months for the control group.
It added the combination therapy was well-tolerated, with no increased side effect burden.
Corcept said it plans to submit a new drug application for the therapy in Q3.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。